Italia markets open in 5 hours 58 minutes

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
5,90-7,59 (-56,26%)
Alla chiusura: 4:30PM GMT

Adverum Biotechnologies, Inc.

800 Saginaw Drive
Redwood City, CA 94063
United States
650 656 9323
http://www.adverum.com

Settore/i
Settore
Impiegati a tempo pieno167

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Ms. Leone D. Patterson M.B.A.Pres, CFO, Principal Financial Officer & Principal Accounting Officer874kN/D1963
Dr. Aaron OsborneChief Medical Officer695,38kN/D1974
Dr. Laurent FischerCEO & DirectorN/DN/D1964
Ms. Angela Thedinga M.B.A., M.P.H.Chief Technology OfficerN/DN/D1982
Ms. Myesha LacyVP of Investor Relations & Corp. CommunicationsN/DN/DN/D
Mr. Peter Soparkar J.D.Chief Legal Officer & Corp. Sec.N/DN/D1971
Ms. Dena HouseVP of HRN/DN/DN/D
Mr. Christopher J. DeRespinoChief Bus. OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Adverum Biotechnologies, Inc. al 3 dicembre 2020 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.